EOHILIA Drug Patent Profile
✉ Email this page to a colleague
When do Eohilia patents expire, and when can generic versions of Eohilia launch?
Eohilia is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are twelve patents protecting this drug.
This drug has one hundred and two patent family members in twenty-six countries.
The generic ingredient in EOHILIA is budesonide. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the budesonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eohilia
A generic version of EOHILIA was approved as budesonide by TEVA PHARMS on November 18th, 2008.
Summary for EOHILIA
International Patents: | 102 |
US Patents: | 12 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EOHILIA |
What excipients (inactive ingredients) are in EOHILIA? | EOHILIA excipients list |
DailyMed Link: | EOHILIA at DailyMed |
Pharmacology for EOHILIA
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for EOHILIA
US Patents and Regulatory Information for EOHILIA
EOHILIA is protected by twelve US patents and two FDA Regulatory Exclusivities.
Patents protecting EOHILIA
Compositions for the treatment of gastrointestinal inflammation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable corticosteroid compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions for the treatment of gastrointestinal inflammation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EOSINOPHILIC ESOPHAGITIS
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EOSINOPHILIC ESOPHAGITIS
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EOSINOPHILIC ESOPHAGITIS
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EOSINOPHILIC ESOPHAGITIS
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EOSINOPHILIC ESOPHAGITIS
Corticosteroid compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF EOSINOPHILIC ESOPHAGITIS
FDA Regulatory Exclusivity protecting EOHILIA
TREATMENT OF ADULT AND PEDIATRIC PATIENTS 11 YEARS OF AGE AND OLDER WITH EOSINOPHILIC ESOPHAGITIS (EOE)
Exclusivity Expiration: ⤷ Sign Up
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | EOHILIA | budesonide | SUSPENSION;ORAL | 213976-001 | Feb 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | EOHILIA | budesonide | SUSPENSION;ORAL | 213976-001 | Feb 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Takeda Pharms Usa | EOHILIA | budesonide | SUSPENSION;ORAL | 213976-001 | Feb 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | EOHILIA | budesonide | SUSPENSION;ORAL | 213976-001 | Feb 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for EOHILIA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Dr. Falk Pharma GmbH | Jorveza | budesonide | EMEA/H/C/004655 Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). |
Authorised | no | no | yes | 2018-01-08 | |
Stada Arzneimittel AG | Kinpeygo | budesonide | EMEA/H/C/005653 Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. |
Authorised | no | no | yes | 2022-07-15 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for EOHILIA
See the table below for patents covering EOHILIA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 2214678 | COMPOSITIONS POUR LE TRAITEMENT D'UNE INFLAMMATION GASTRO-INTESTINALE (COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL INFLAMMATION) | ⤷ Sign Up |
Spain | 2781949 | ⤷ Sign Up | |
Canada | 2705681 | COMPOSITIONS CORTICOSTEROIDIENNES (CORTICOSTEROID COMPOSITIONS) | ⤷ Sign Up |
Denmark | 2214677 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EOHILIA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2435024 | 2021C/518 | Belgium | ⤷ Sign Up | PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210 |
2435024 | SPC/GB21/029 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210 |
2435024 | 2190014-7 | Sweden | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210 |
0613371 | SPC/GB02/033 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FORMOTEROL (OPTIONALLY IN THE FORM OF THE FREE BASE OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, OR A SOLVATE OF SUCH FREE BASE OR SALT ESPECIALLY AS FORMOTEROL FUMARATE DIHYDRATE) AND BUDESONIDE; REGISTERED: SE SE16047, 16048 20000825; UK PL17901/0091 20010515; UK PL17901/0092 20010515 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |